ClinicalTrials.gg
CompletedNCT02497469Updated Jan 28, 2020Results posted

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

A Phase 3 interventional study of Vedolizumab and Adalimumab placebo in Colitis, Ulcerative, sponsored by Takeda. Completed at 330 sites in 34 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
771
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
4th of 38
771 · median 110
Started
2015
with 2 others
Phase 3
14 of 38
3 open now
Registered
6th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 6th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have ulcerative colitis. This study will look at the stool frequency, rectal bleeding and findings on endoscopy of people who take vedolizumab compared to those who take adalimumab.

The study will enroll approximately 658 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Vedolizumab 300 mg IV
  • Adalimumab 160 mg on Day 1 followed by 80 mg on Week 2 then 40 mg every 2 weeks SC

All participants will receive 1 intravenous infusion on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. All participants will also receive 4 SC injections on Day 1 or 2 SC injections each on Days 1 and 2, followed by 2 SC injections in 1 day on Week 2 and then 1 SC injection every 2 weeks for up to Week 50. All participants will be asked to record the symptoms of ulcerative colitis in a daily diary.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 79 weeks. Participants will make approximately 11 visits to the clinic, and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of ulcerative colitis established at least 3 months prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Has moderately to severely active ulcerative colitis as determined by a Mayo score of 6 to 12 with an endoscopic subscore greater than or equal to >=2 within 14 days prior to the randomization.
  3. Has evidence of ulcerative colitis proximal to the rectum (>=15 centimeter [cm] of involved colon).
  4. With extensive colitis (up to the hepatic flexure) or pancolitis of >8 years duration or left-sided colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit (may be performed during the Screening Period).
  5. The participant:

    1. Has had previous treatment with tumor necrosis factor- alpha (TNF-alpha) antagonists without documented clinical response to treatment (example, due to lack of response [primary nonresponders], loss of response, or intolerance [secondary nonresponders]), or
    2. Has previously used a TNF-alpha antagonists (except adalimumab), and discontinued its use due to reasons other than safety, or
    3. Is naïve to TNF-alpha antagonist therapy but is failing current treatment (example, , 5-aminosalicylate [5-ASA], or immunomodulators).

Exclusion criteria

Exclusion Criteria:

  1. Clinical evidence of abdominal abscess or toxic megacolon at Screening.
  2. Has had an extensive colonic resection, subtotal or total colectomy.
  3. Has had ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  4. Has a diagnosis of Crohn's colitis or indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.
  5. Has received any of the following for the treatment of underlying disease within 30 days of randomization:

    1. Non-biologic therapies (example, cyclosporine, tacrolimus, thalidomide) other than those specifically listed in Section Permitted Medications For Treatment of UC.
    2. An approved non-biologic therapy in an protocol.
  6. Has received any investigational or approved biologic or biosimilar agent within 60 days or 5 half lives prior to the screening (whichever is longer).
  7. Has previously received natalizumab, efalizumab, adalimumab, AMG-181, anti-mucosal addressin cell adhesion molecule-1 antibodies, or rituximab.
  8. Has previously received vedolizumab.
  9. Has history or evidence of adenomatous colonic polyps that have not been removed, or colonic mucosal dysplasia.
  10. Evidence of an active infection during Screening.
  11. Evidence of, or treatment for, Clostridium difficile (C. difficile) or other intestinal pathogen within 28 days prior to the 1st dose of study drug.
  12. Has chronic virus (HBV) infection* or chronic virus (HCV) infection (* HBV immune participants, ie, being hepatitis B surface antigen [HBsAg], may participate).
  13. Has active or latent TB, regardless of treatment history.
  14. Has used a topical (rectal) treatment with (5-ASA) or enemas/suppositories within 2 weeks of the administration of the 1st dose of study drug.
  15. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist prior to the administration of the first dose of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
771 participants (actual)

Study arms

  • Experimental
    Vedolizumab IV 300 mg

    Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.

    Drug: Vedolizumab · Drug: Adalimumab placebo

  • Active comparator
    Adalimumab SC 160/80/40 mg

    Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.

    Drug: Adalimumab · Drug: Vedolizumab placebo

Interventions

  • Vedolizumab infusion

  • DrugAdalimumab placebo

    Adalimumab placebo-matching injection

  • Adalimumab injection

  • DrugVedolizumab placebo

    Vedolizumab placebo-matching infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission

    Clinical remission was defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Who Achieved Mucosal Healing

    Mucosal healing was defined as a Mayo score endoscopic subscore of \<= 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 52

  2. Percentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission

    Corticosteroid-free remission was defined as participants using oral corticosteroids at Baseline (Week 0) who had discontinued oral corticosteroids and were in clinical remission at Week 52. Clinical remission was defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 52

07

Results

Posted Oct 10, 2019

Participant flow

Participants took part in the study at 205 investigative sites worldwide from 29 June 2015 up to 18 January 2019.

Participant flow — Overall Study
MilestoneAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Started386385
Safety analysis set386383
Completed217270
Not completed169115
Withdrew: Randomized but not treated02
Withdrew: Pretreatment event/adverse event1816
Withdrew: Leukopenia or lymphopenia10
Withdrew: Significant protocol deviation45
Withdrew: Lost to follow-up144
Withdrew: Voluntary withdrawal3941
Withdrew: Pregnancy11
Withdrew: Lack of efficacy8640
Withdrew: Reason not specified66

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission

Clinical remission was defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission
percentage of participantsAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Percentage of Participants Who Achieved Clinical Remission22.5 (18.5 to 27.0)31.3 (26.7 to 36.2)
Statistical analysis
  • Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg · Cochran-Mantel-Haenszel · p = 0.0061 · Adjusted difference: 8.8 · 95% CI 2.5 to 15.0
SecondaryPercentage of Participants Who Achieved Mucosal Healing

Mucosal healing was defined as a Mayo score endoscopic subscore of \<= 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Mucosal Healing
percentage of participantsAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Percentage of Participants Who Achieved Mucosal Healing27.7 (23.3 to 32.5)39.7 (34.8 to 44.8)
Statistical analysis
  • Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg · Cochran-Mantel-Haenszel · p = 0.0005 · Adjusted difference: 11.9 · 95% CI 5.3 to 18.5
SecondaryPercentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission

Corticosteroid-free remission was defined as participants using oral corticosteroids at Baseline (Week 0) who had discontinued oral corticosteroids and were in clinical remission at Week 52. Clinical remission was defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission
percentage of participantsAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Percentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission21.8 (14.8 to 30.4)12.6 (7.1 to 20.3)
Statistical analysis
  • Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg · Cochran-Mantel-Haenszel · p = 0.0641 · Adjusted difference: -9.3 · 95% CI -18.9 to 0.4

Adverse events

Collected over From first dose of study drug and up to 126 days after the last dose (Up to 68 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab SC, 160/80/40 mg0/386 (0%)53/386 (13.7%)114/386 (29.5%)
Vedolizumab IV 300 mg1/383 (0.3%)42/383 (11%)103/383 (26.9%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Colitis ulcerativeGastrointestinal disorders25/38619/383
AnaemiaBlood and lymphatic system disorders4/3861/383
Abdominal painGastrointestinal disorders1/3863/383
Cytomegalovirus infectionInfections and infestations1/3863/383
DiarrhoeaGastrointestinal disorders0/3862/383
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/3862/383
Nerve root compressionNervous system disorders0/3862/383
PneumoniaInfections and infestations2/3860/383
Angina pectorisCardiac disorders0/3861/383
PericarditisCardiac disorders0/3861/383
Most frequent other events
Most frequent other events
EventAdalimumab SC, 160/80/40 mgVedolizumab IV 300 mg
Colitis ulcerativeGastrointestinal disorders42/38626/383
NasopharyngitisInfections and infestations30/38627/383
HeadacheNervous system disorders21/38627/383
AnaemiaBlood and lymphatic system disorders23/38619/383
Upper respiratory tract infectionInfections and infestations17/38620/383

Baseline characteristics

Randomized Set included all participants who were randomized into the study, regardless of whether they received any dose of the study drug.

Age, Continuous
Age, Continuous(years)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Mean40.5 ± 13.4440.8 ± 13.7440.7 ± 13.59
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Female170151321
Male216234450
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Hispanic or Latino6814
Not Hispanic or Latino392362
Unknown or Not Reported341354695
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
American Indian or Alaska Native11415
Asian303262
Native Hawaiian or Other Pacific Islander101
Black or African American325
White341345686
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Australia358
Hong Kong145
Korea, Republic Of191635
Taiwan, Province Of China415
Czech Republic13821
Hungary161632
Poland7885163
Serbia111829
Slovakia5813
Bosnia213
Bulgaria10616
Croatia11516
Israel91322
Romania6612
Russia414485
Turkey9514
Ukraine263965
Canada182038
United States422971
Argentina134
Colombia224
Mexico9312
France4610
Germany369
Italy91120
Latvia6713
Lithuania7714
Portugal9413
United Kingdom235
Denmark8311
Belgium011
Netherlands101
Spain101
Height
Height(cm)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Mean170.5 ± 9.65172.0 ± 9.90171.3 ± 9.79
Weight
Weight(kg)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Mean73.43 ± 18.37472.67 ± 16.95273.05 ± 17.673
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Adalimumab SC, 160/80/40 mgVedolizumab IV 300 mgTotal
Mean25.17 ± 5.64624.46 ± 4.78624.82 ± 5.244

2 further baseline measures are reported on the registry.

08

Study locations

330 sites
  • IMC - Diagnostic and Medical Clinic
    Mobile, Alabama 36604, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 85037, United States
  • Arkansas Primary Care Clinic, PA
    Little Rock, Arkansas 72204, United States
  • WCCT Global (PH 1 Unit)
    Costa Mesa, California 92626, United States
  • California Medical Research Associates Inc.
    Northridge, California 91324, United States
  • Sutter Institute for Medical Research
    Sacramento, California 95816, United States
  • Rocky Mountain Gastroenterology
    Lakewood, Colorado 80214-5434, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Innovative Medical Research of South Florida, Inc.
    Aventura, Florida 33180, United States
  • Advanced Clinical Research of Miami
    Doral, Florida 33172, United States
  • Wellness Clinical Research
    Hialeah Gardens, Florida 33016, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 34452, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33773-1615, United States
  • South Florida Research Phase I-IV
    Miami Springs, Florida 33166, United States
  • Gastro Health
    Miami, Florida 33143, United States
  • Medical Professional Clinical Research
    Miami, Florida 33165, United States
  • Tellus Clinical Research, Inc.
    Miami, Florida 33173, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • BRCR Medical Center, Inc.
    Plantation, Florida 33322, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Gastroenterology of Southern Associates
    New Albany, Indiana 47150, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Research Concierge, LLC
    Owensboro, Kentucky 42303, United States
  • Gastroenterology Associates, LLC
    Baton Rouge, Louisiana 70809, United States
  • Lafayette General Medical Center
    Lafayette, Louisiana 70503, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71103, United States
  • Digestive Disease Associates
    Catonsville, Maryland 21228, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health and Nutritional Excellence
    Troy, Michigan 48098, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Digestive Health Center PA
    Ocean Springs, Mississippi 39564, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 64012, United States
  • Truman Medical Centers, Inc.
    Kansas City, Missouri 64108, United States
  • Alegent Creighton Clinic Gastroenterology
    Omaha, Nebraska 68124, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Mount Sinai - PRIME
    Lake Success, New York 10029, United States
  • Digestive Disease Care
    New Hyde Park, New York 11040, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7080, United States
  • Consultants for Clinical Research Inc.
    Cincinnati, Ohio 45219, United States
  • Ohio State University Clinical Trials Management Office
    Columbus, Ohio 43210, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • Gastro-Enterology Research of Lima
    Lima, Ohio 45806, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • The Oregon Clinic-West Hills Gastroenterology
    Portland, Oregon 97225, United States
  • Main Line Gastroenterology Associates
    Malvern, Pennsylvania 19355, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Invocare Clinical Research Center
    West Columbia, South Carolina 29169, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1375, United States
  • Texas Digestive Disease Consultants - Dallas
    Dallas, Texas 75231, United States
  • Baylor University Hospital
    Dallas, Texas 75246, United States
  • MedResearch, Inc
    El Paso, Texas 79935, United States
  • Gastroenterology Consultants of South Texas, PA
    Harlingen, Texas 78550, United States
  • Gulf Coast Research Group LLC
    Houston, Texas 77098, United States
  • Texas Digestive Disease Consultants - Irving
    Irving, Texas 75039, United States
  • Advanced Clinical Research Associates
    Plano, Texas 75093, United States
  • Gastroenterology Research of San Antonio, LLC
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - Southlake
    Southlake, Texas 76092, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • Virginia Mason Seattle Main Clinic
    Seattle, Washington 98101, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Allegiance Research Specialists, LLC
    Milwaukee, Wisconsin 53226, United States
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Mar del Plata, Buenos Aires B7600FZ, Argentina
  • Instituto Medico CER
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Expertia S.A- Mautalen Salud e Investigacion
    Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
  • Centro de Investigaciones Clinicas Instituto del Corazon
    Cordoba, X5000EVQ, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Tennyson Centre Day Hospital
    Bedford Park, South Australia 5042, Australia
  • Ballarat Base Hospital
    Ballarat, Victoria 3350, Australia
  • Monash Medical Centre Moorabbin
    Clayton, Victoria 3168, Australia
  • St Frances Xavier Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, 88000, Bosnia and Herzegovina
  • University Clinic Centre Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • MHAT - Pazardzhik AD
    Pazardzhik, 4400, Bulgaria
  • MHAT 'Avis Medica' OOD
    Pleven, 5800, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • "City Clinic UMHAC" EOOD
    Sofia, 1407, Bulgaria
  • Medical Center "Excelsior", OOD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria

Showing the first 100 of 330 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dulai PS, Feagan BG, Sands BE, Chen J, Lasch K, Lirio RA. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023 Feb;21(2):456-466.e7. doi: 10.1016/j.cgh.2022.07.027. Epub 2022 Aug 4. PubMed 35934286 ↗
  • Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 2021 Oct;161(4):1156-1167.e3. doi: 10.1053/j.gastro.2021.06.015. Epub 2021 Jun 16. PubMed 34144047 ↗
  • Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Toruner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. PubMed 31553834 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Sep 2018, 38 months.

Results were first posted in Oct 2019, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 38 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2015
First posted
Jul 14, 2015
StartActual
Jun 29, 2015
Primary completionActual
Sep 26, 2018
CompletionActual
Jan 18, 2019
Results first posted
Oct 10, 2019
Last update
Jan 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02497469
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Jun 29, 2015
Primary completion
Sep 26, 2018
Completion
Jan 18, 2019
Results posted
Oct 10, 2019
Last update
Jan 28, 2020

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion